Navigation Links
Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
Date:7/1/2009

l sale of the U.S. business and Encorium OY and our expectations regarding the effects of such transactions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the timing of the closing, if any, of the transactions; (ii) the completion to the purchasers satisfaction of due diligence; (iii) the acquisition by us of a fairness opinion relating to the purchase price for the sale of Encorium OY; (iv) our ability to negotiate definitive agreements with the Purchasers; (v) the possibility that the transactions may not close; and (vi) the risk that any distributions to stockholders in connection with the transactions will be significantly less than the current stock price.

Additional risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and price
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Avicena Group to Present at Noble Financial Conference
9. Chrome Group to Seek Listing for Some of its Subsidiaries
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Pioneering Field, BETHESDA, Md., Sept. 10 ... an ownership interest in,ClinResearch GmbH, a global leader ... clinical trials. Headquartered in Cologne, Germany,with more than ... programs over the past seven years. ClinResearch,s co-founder,Reinhard ...
... a broad array, of biometric enrollment ... Sept. 10 Aware, Inc. (Nasdaq:,AWRE), a global ... long history of success in providing high-quality,innovative software ... comprehensive suite of products in their booth (#501) ...
... September 13 to Discuss Phase 1 Trial and Other Major ... ... CA, Sept. 10 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) today announced the ... tolerability of new,HspE7 (HspE7 dosed with an adjuvant) in 24 patients ...
Cached Biology Technology:United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 3Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 4Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 5Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 6
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... retreat from equatorial seas and oceans as the Earth continues ... Working on clues in the fossil coral record from ... the last two ice ages about 125,000 years ago, the ... near the equator. "When the climate warmed rapidly during ...
... researchers have revealed the secrets of survival of an ... desert, and suggest that recent violence in Mali may ... study, to appear in January,s edition of Biological ... System (GPS) collars. Its findings advance conservation efforts for ...
... 12, 2012 Cell aging, or cellular senescence, has ... tumor development. Activated oncogenes are able to induce senescence, ... could play a key role in future cancer therapy. ... the regulation of OIS. This study is published online ...
Cached Biology News:Scary news for corals -- from the Ice Age 2Violence in Mali threatening survival of endangered elephants 2Previously unknown mechanism identified in oncogene-induced senescence 2
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
EDG-6 (1)...
Complexin-1/2 (FL-134)...
Biology Products: